COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors
Open Access
- 1 September 2000
- Vol. 47 (3), 320-325
- https://doi.org/10.1136/gut.47.3.320
Abstract
No abstract availableThis publication has 57 references indexed in Scilit:
- Cyclo‐oxygenase‐2: pharmacology, physiology, biochemistry and relevance to NSAID therapyBritish Journal of Pharmacology, 1999
- COX-2 inhibitorsThe Lancet, 1999
- Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin☆☆☆Gastroenterology, 1998
- Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in ratsBritish Journal of Pharmacology, 1998
- Suppression of Intestinal Polyp Development by Nimesulide, a Selective Cyclooxygenase‐2 Inhibitor, in Min MiceJapanese Journal of Cancer Research, 1997
- Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.Journal of Clinical Investigation, 1997
- NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, EICOSANOIDS, AND COLORECTAL CANCER PREVENTIONGastroenterology Clinics of North America, 1996
- Double-blind, placebo-controlled comparison of the safety and efficacy of orally administered etodolac and nabumetone in patients with active osteoarthritis of the kneeClinical Therapeutics, 1995
- The role of nonsteroidal anti-inflammatory drugs in colorectal cancer preventionEuropean Journal Of Cancer, 1995
- Sulindac for polyposis of the colonJournal of Surgical Oncology, 1983